Payment overview · 2025
General Payments
$422.65
16 reported records · 6 companies
Healthcare provider profile · identity verified
Debora Kay Katz
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WEST UNION, OH · NPI 1174853014
Verified facts
What the public records show
CMS Open Payments records show Debora Kay Katz received $422.65 in general payments during 2025 across 16 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Vraylar by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Caplyta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $157.32 | 37.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.54 | 17.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.14 | 14.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.36 | 12.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.87 | 12.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $27.42 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $422.65 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $104.77 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.54 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $61.14 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.36 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.87 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 150 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
150 | 19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 397 | 47 |
| Trazodone Hcl | Trazodone Hcl | 308 | 44 |
| Sertraline Hcl | Sertraline Hcl | 267 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 257 | 30 |
| Gabapentin | Gabapentin | 233 | 35 |
| Clonazepam | Clonazepam | 227 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 205 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 174 | 23 |
| Buspirone Hcl | Buspirone Hcl | 158 | 23 |
| Olanzapine | Olanzapine | 156 | 20 |
| Vraylar | Cariprazine Hcl | 150 | 19 |
| Lisinopril | Lisinopril | 149 | 18 |
| Lorazepam | Lorazepam | 149 | 24 |
| Omeprazole | Omeprazole | 143 | 18 |
| Lamotrigine | Lamotrigine | 130 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 28 |
| Aripiprazole | Aripiprazole | 127 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 14 |
| Risperidone | Risperidone | 121 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 119 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 13 |
| Bupropion Xl | Bupropion Hcl | 107 | 13 |
| Diazepam | Diazepam | 102 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 13 |
| Lithium Carbonate | Lithium Carbonate | 93 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | suppressed |
| Furosemide | Furosemide | 92 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 91 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 89 | 11 |
| Prazosin Hcl | Prazosin Hcl | 87 | 20 |
| Potassium Chloride | Potassium Chloride | 86 | 11 |
| Olanzapine Odt | Olanzapine | 82 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 81 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 80 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 11 |
| Montelukast Sodium | Montelukast Sodium | 76 | suppressed |
| Jardiance | Empagliflozin | 73 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 71 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 59 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | suppressed |
| Perphenazine | Perphenazine | 52 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 51 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 50 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 47 | suppressed |
| Losartan Potassium | Losartan Potassium | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Famotidine | Famotidine | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | suppressed |
| Paliperidone Er | Paliperidone | 41 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 33 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Abilify Maintena | Aripiprazole | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Haloperidol | Haloperidol | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Caplyta | Lumateperone Tosylate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $422.65 · 16 records | E.R. Squibb & Sons, L.L.C. | Auvelity, CAPLYTA, COBENFY, INGREZZA, REXULTI, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error